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Invited Review
The nutrition management of patients facing critical illness, 
abdominal surgery, or intestinal failure can be particularly chal-
lenging as their pathologic state leaves the intestine as a nonviable 
route for nutrient delivery. Failure to provide adequate nutrition 
may result in diminished immune function, increased complica-
tions, and extended hospitalizations.1,2 When clinically feasible, 
enteral feeding provides the ideal method of nutrient delivery.2-6 
Even among critically ill patients, where “bowel rest,” or the with-
holding of enteral feeding, has previously been practiced, the early 
initiation of feeds within 48 hours of intensive care unit (ICU) 
admission has more recently been shown to reduce mortality and 
costs compared with delayed feeding.7,8 These results have been 
codified by the American Society for Parenteral and Enteral 
Nutrition (A.S.P.E.N), whose most recent recommendations from 
their consensus meeting in 2009 include the early initiation of 
enteral feeds in the postoperative setting unless specific contrain-
dications are present.9
Parenteral Nutrition: A Necessity
When enteral feeding is not possible, the parenteral route 
becomes a life-sustaining method of delivering calories and 
nutrients. Parenteral nutrition (PN)—wherein enteral nutrient 
delivery is withheld and nutrition is supplied intravenously—is 
required for >350,000 patients per year in the United States.10 
Of these, >10% require home-based, long-term PN. In critical 
care studies, the use of early PN resulted in reduced need for 
mechanical ventilation, improved quality of life, and reduced 
costs, benefitting patients who otherwise would not have been 
able to receive enteral nutrition until day 3 of ICU admis-
sion.11,12 These findings were recently confirmed in the 
CALORIES trial, a large randomized trial that found no signifi-
cant difference in infectious complications or 30-day mortality 
between early PN versus enteral nutrition among the critically 
ill.13 These findings may be due to high rates of enteral feeding 
intolerance and procedural delay, which can prevent critically 
ill patients from attaining nutrient fulfillment when relying on 
the enteral route alone. No matter the cause, these results 
support the premise that when adequate nutrition cannot be 
delivered via the enteral route, PN is a necessary intervention.
Infectious Risks
Outside of the critical care setting, the adverse effects of PN 
become increasingly significant, with metabolic derange-
ments, hepatic dysfunction, and systemic infection posing the 
609904 NCPXXX10.1177/0884533615609904Nutrition in Clinical PracticeDemehri et al
research-article2015
From the 1Department of Surgery, University of Michigan Health 
System, Ann Arbor, Michigan.
Financial disclosure: None declared.
This article originally appeared online on September 30, 2015.
Corresponding Author:
Daniel H. Teitelbaum, MD, Section of Pediatric Surgery, University of 
Michigan, Mott Children’s Hospital, 1540 E. Hospital Dr, SPC 4211, 
Ann Arbor, MI 48109-4211, USA. 
Email: dttlbm@umich.edu
Changes to the Intestinal Microbiome With Parenteral 
Nutrition: Review of a Murine Model and Potential  
Clinical Implications
Farokh R. Demehri, MD1; Meredith Barrett, MD1; and Daniel H. Teitelbaum, MD1
Abstract
Parenteral nutrition (PN) dependence, while life sustaining, carries a significant risk of septic complications associated with epithelial 
barrier dysfunction and translocation of gut-derived microbiota. Increasing evidence suggests that PN-associated changes in the intestinal 
microbiota play a central role in the breakdown of the intestinal epithelial barrier. This review outlines the clinical and experimental 
evidence of epithelial barrier dysfunction with PN, the role of gut inflammatory dysregulation in driving this process, and the role of 
the intestinal microbiome in modulating inflammation in the gut and systemically. The article summarizes the most current work of our 
laboratory and others and describes many of the laboratory findings behind our current understanding of the PN enteral environment. 
Understanding the interaction between nutrient delivery, the intestinal microbiome, and PN-associated complications may lead to the 
development of novel therapies to enhance safety and quality of life for patients requiring PN. (Nutr Clin Pract. 2015;30:798-806)
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most significant risks.2-4,14-16 A seminal Veterans Affairs study 
found that patients receiving PN who had mild or moderate 
malnutrition had an increased rate of infectious complica-
tions, including urinary tract infections, wound infections, and 
pneumonia.14 Importantly, these complications were not due to 
central access, a necessity for delivery of PN, but instead 
implicated a systemic propensity for the development of multi-
site infections.
As the duration of PN dependence increases, so does the 
associated risk of infectious complications.17 For example, 
children requiring long-term PN have up to a 27% cumulative 
mortality rate, with hepatic failure and systemic infections 
contributing significantly to this rate.18,19 The clinical man-
agement of PN-dependent patients, therefore, focuses on 
reevaluating the need for PN and advancing enteral feeding 
when tolerated.
While the risk of septic complications is well-established 
with PN, the origin of these infections is incompletely under-
stood. Increasing evidence implicates the intestinal microbiota 
as a possible source. The largest source of bacteria in the human 
body, the intestinal microbiome exists normally as a symbiotic 
community. When this symbiotic relationship is disturbed, how-
ever, altered gut microbiota may drive systemic pathological 
responses, including inflammatory bowel disease, obesity, car-
diovascular disease, and sepsis.20,21 In surgical patients, 
decreased diversity of the microbiome has been associated with 
postoperative complications, including anastomotic leaks.22
Loss of Barrier Function
A common finding in PN-dependent animal models involves 
cultured organisms from the blood that are normally found 
within the gut.23 This finding has implied an enteric origin of 
these bacteria, which has been supported by animal studies for 
nearly 30 years.24,25 Alverdy et al25 described the translocation 
of gut-derived bacteria to mesenteric lymph nodes in up to 
two-thirds of PN-dependent rats, compared with one-third of 
those receiving both enteral nutrition and PN. Rats receiving 
only enteral nutrition had no such evidence of translocation.25-27 
This classic study has since been repeated in other animal mod-
els, indicating a PN-associated loss of epithelial barrier func-
tion (EBF) as a key factor in the development of septic 
complications from PN dependence.28 This loss of EBF has 
been quantified using ex vivo measurements of intestinal tran-
sepithelial resistance23—findings that have recently been repli-
cated in unfed human intestinal tissue.29
In cell-culture models, this translocation has been observed 
more directly. The exposure of cultured intestinal epithelial 
cells (IECs) to bacteria induces epithelial breakdown and bacte-
rial translocation in a dose- and species-dependent manner, with 
gram-negative enteric bacteria (dominant bacteria in PN depen-
dence) exhibiting high rates of translocation.30 Supplementing 
the enteral microenvironment with dietary fiber decreases the 
rate of bacterial translocation from the gut.31 These findings 
suggest that it is the lack of enteral nutrition that drives the loss 
of EBF in the PN-dependent state, as opposed to the delivery of 
PN itself. Certain enteric microbiota also contribute to bacterial 
translocation by directly injuring the epithelial barrier. Enteric 
microbiota and bacteria-derived toxins can then translocate 
across this dysfunctional epithelial barrier, manifesting clini-
cally as endotoxemia, bacteremia, and potentially sepsis.
Understanding of how PN-associated epithelial barrier dys-
function occurs, particularly the evidence that changes in the 
bacterial population drive this process, has been gained through 
a combination of animal and human studies. Our laboratory 
has used a mouse model with which PN is delivered intrave-
nously and all enteral nutrition is withheld.32 These animals are 
compared with controls that receive intravenous saline and are 
allowed an oral diet. Importantly, the total nutrient and calorie 
delivery to all animals is equal; therefore, any deleterious 
effects are due to the method of nutrition delivery: PN versus 
enteral nutrition. This model, and others similar to it, have pro-
vided insight into the loss of EBF, inflammatory dysregulation, 
and changes in the mucosa-associated microbiome that occur 
with PN—findings that are increasingly confirmed in humans.
Intestinal epithelial barrier is a functional term, describing 
the role of the epithelium in protecting the host against the 
invasion of gut-dwelling bacteria and their products.33 The 
structural components of the epithelial barrier include a con-
tinually renewing single layer of epithelial cells34; tight junc-
tion proteins, which regulate the movement of ions and small 
molecules through the paracellular space35; a layer of mucins 
comprised of glycoproteins and produced by goblet cells36; 
Paneth cell–derived antimicrobial factors, including lysozyme 
and α-defensins37; and secretory immunoglobulin A produced 
by gut-associated lymphoid tissue.38 Each of these factors 
plays a role in maintaining intraluminal homeostasis through 
interactions with the microbiome, influencing the relative 
abundance of individual bacterial strains.
An example of one such interaction is the intestinal mucus 
layer, which serves as a medium for bacterial colonization, 
with several bacterial species using mucin-derived oligosac-
charides as a carbon source. In turn, intestinal bacteria stimu-
late the epithelium to secrete additional mucus sugars.39,40 In this 
manner, mucins function as epithelium-derived “prebiotics” by 
providing metabolic substrate for certain commensal bacteria 
and therefore influencing the makeup of the microbiome.33 
Disruption of this relationship between microbiota and mucin 
degradation allows pathogenic bacteria to expand.41
Similarly, secretory immunoglobulin A (sIgA) plays a key 
role in shaping intestinal microbial ecology. Antigen-specific 
production of sIgA occurs via T-cell-dependent pathways, and 
it is secreted into the luminal environment, where it interacts 
with gut microbiota. sIgA acts by binding to certain bacteria 
and microbial products, preventing enteroinvasion. Like mucin 
secretion, sIgA is influenced by the presence of intestinal 
microbiota, with germ-free mice demonstrating low levels in 
the gut until they are colonized with intestinal bacteria.42
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Even at the tight junction level, a complex interaction 
between microbiota and host function exists (Figure 1).43 Tight 
junction integrity is preserved through interactions of multiple 
different barrier proteins and IECs.33 Tight junction permeabil-
ity appears to be dependent on microbial signaling—bacteria 
and their products modify permeability and ion selectivity. 
This manifests electrophysiologically as altered transepithelial 
resistance. This phenomenon has been demonstrated by inocu-
lating cultured intraepithelial cells with bacterial metabolites, 
which leads to increased expression of junctional-associated 
protein occludin bolstering the tight junction function.44 
Conversely, incubation of human intestinal organoids (tissue 
grown through pluripotent stem cells) with Clostridium diffi-
cile leads to a marked deterioration of EBF.45 Therefore, an 
interesting relationship exists in which tight junctions limit the 
translocation of small molecules, including bacteria-derived 
products, yet their expression and function are altered by these 
same products and their source bacteria.
In the setting of enteral deprivation with PN, multiple ele-
ments of the intestinal epithelial barrier are compromised. 
PN-dependent mice demonstrate diminished secretion of key 
antimicrobial factors phospholipase and lysozyme, leading to 
reduced bactericidal activity and increased susceptibility to 
bacterial enteroinvasion.15,46,47 Perhaps reflecting a compensa-
tory defensive response by the epithelium, PN dependence has 
been shown to lead to an increase in goblet cell (immune mod-
ulators) numbers.29,48 Tight junction integrity is reduced in the 
PN-dependent setting, with loss of multiple components of the 
junctional complex resulting in decreased barrier function.49,50 
Finally, the epithelial cell layer itself is compromised during 
the administration of PN, with decreased intraepithelial cell 
proliferation coupled with cell atrophy and death.51,52 These 
Figure 1. Mechanisms of parenteral nutrition–induced loss of epithelial barrier function. In the setting of parenteral nutrition 
dependence, there is a shift in the microbial population to a gram-negative Proteobacteria-predominant population. Toll-like receptors 
are activated by lipopolysaccharide from gram-negative bacteria, resulting in increased expression of tumor necrosis factor-α (TNF-α). 
The increase is also associated with an up-regulation of TNF-α receptors (TNFR) on the epithelial cells. This results in tight junction 
breakdown via decreased claudins and occludin expression. Claudins and occludin are cytoskeletal proteins that act as cell-to-cell 
adhesion molecules between intestinal epithelial cells; their down-regulation allows for translocation of bacteria outside of the bowel 
lumen. Occludin is broken down, and fragments of the molecules are found within the cytoplasm of intestinal epithelial cells.
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structural changes in the intestinal epithelial barrier with PN 
dependence result in the functional outcome of increased 
bowel wall permeability and manifest clinically as the bacterial 
translocation associated with PN.53 As previously mentioned, 
current data suggest that the loss of EBF seen with PN depen-
dence is the result of enteral deprivation as opposed to the PN 
solution. This has been corroborated by administering “tro-
phic” feeding in a rodent model, consisting of 25% of caloric 
needs. This minimal enteral nutrition restored tight junction 
integrity and preserved EBF compared with full enteral 
deprivation.54
Adding to the loss of EBF is the up-regulation of proinflam-
matory cytokines tumor necrosis factor-α (TNF-α) and 
interferon-γ (IFN-γ), which each independently induce loss of 
tight junctions and increased bowel wall permeability.55 Their 
expression is increased 3-fold in the PN-dependent mucosa. 
The subsequent epithelial barrier dysfunction is mitigated in 
IFN-γ-knockout mice.32,56 Similarly, TNF-α expression is 
increased in the PN-dependent setting.57 Expression of this 
cytokine is associated with apoptosis and mucosal atrophy 
via activation of a Toll-like receptor-4 (TLR-4) signaling 
pathway.57,58 Activation of this inflammatory cascade recruits 
immunocytes, further contributing to immune dysregulation.59 
This proinflammatory state has been observed in unfed human 
intestine as well, which demonstrated significant increases in 
TNF-α and TLR-4 compared with matched fed intestine from 
the same patient.29
In addition to the increase in proinflammatory signaling 
driven by TNF-α and IFN-γ, a reduction in the counterinflam-
matory cytokine interleukin-10 (IL-10) occurs in the 
PN-dependent setting. IL-10 expression is necessary to main-
tain EBF,60 with IL-10 knockout mice demonstrating barrier 
breakdown and gut inflammation.61 PN dependence results in a 
decline in mucosal IL-10, with a subsequent increased EBF 
with administration of exogenous IL-10.49 Compounding the 
inflammatory cytokine imbalance, PN dependence results in a 
loss of mucosal growth factors. Epidermal growth factor, kera-
tinocyte growth factor, and glucagon-like growth factor are all 
down-regulated in PN dependence. Extensive study has revealed 
an imbalance between proinflammatory and anti-inflammatory 
cytokines and loss of growth hormone signaling in the PN 
model to which the loss of growth factors is attributed.62,63 The 
above interactions are a brief overview of the very complex 
changes seen in PN dependence, the intricacies of which are 
beyond the scope of the current review. We encourage referral 
to above studies referenced for the mechanistic descriptions of 
changes involved.
Microbial Population Changes
The PN-associated proinflammatory state within the intestinal 
epithelium and resulting loss of EBF increase the susceptibility 
of the epithelial barrier to enteroinvasion and translocation of 
microbiota-derived products. This mechanism accounts for the 
microbiota as the final actor in PN-associated bacteremia, as 
bacteria remain passive within the lumen until epithelial bar-
rier loss occurs. Increasing evidence suggests, however, that 
the PN-dependent state leads to a primary, significant shift in 
the makeup of the intestinal microbiome. While a causal rela-
tionship has not been definitively demonstrated, it is possible 
that the expansion of pathogenic microbial populations drives 
the proinflammatory epithelial state and subsequent loss of 
barrier function, subsequently allowing for translocation and 
further inflammatory insult.
In a mouse model, 6 days of PN dependence results in an 
altered small bowel mucosa-associated microbiome. This is 
characterized, at the phylum level, by an expansion of 
Proteobacteria and Bacteroidetes while there is a relative loss 
of Firmicutes.58 Similar changes were observed in 
PN-dependent rats, with a shift in the ratio of Firmicutes to 
Bacteroidetes in favor of Bacteroidetes after 14 days of PN 
compared with fed control animals.64 A neonatal pig model has 
also showed a significant change in the gut microbiome with 
PN, characterized by a reduction in bacterial concentration 
throughout the intestine, as well as loss of bacterial diversity at 
the genus level.65 Interestingly, the PN-dependent pigs demon-
strated higher levels of colonization with toxin-expressing C 
difficile. These various animal models consistently demon-
strate reduced bacterial diversity with a relative expansion of 
pathogenic microbiota in the PN-dependent setting.
To date, limited data exist on the impact of PN on the human 
intestinal microbiome. Most human studies have evaluated 
fecal microbiota, which represent a distinct community from 
the small bowel mucosa-associated microbiota.66,67 Interesting 
trends still result and parallel those of animal studies. In a 
study of patients with Crohn’s disease, Shiga et al68 found 
reduced species diversity of the fecal microbiome after initia-
tion of PN and a significant increase in the population of 
Enterococcus species. Engstrand Lilja et al69 recently evalu-
ated the fecal microbiome of PN-dependent children with short 
bowel syndrome—a significant cause of PN dependence in the 
pediatric population—and compared these with healthy sib-
lings. Interestingly, this study found a marked reduction in bac-
terial diversity in PN-dependent children compared with both 
healthy siblings and those with short bowel syndrome who had 
transitioned to an enteral diet. Along with a loss of diversity, 
the PN-dependent children were found to have a marked 
increase in the abundance of Enterobacteriaceae. This family 
of gram-negative Proteobacteria includes pathogens such as 
Salmonella, Shigella, and Proteus, which have been previously 
found in mouse models.58
It is hypothesized that the reduced bacterial diversity and 
relative abundance of Proteobacteria in the PN-dependent 
mucosa-associated intestinal microbiome may be a result of a 
marked change in available nutrients for bacterial utilization. 
The gut microbiome is highly sensitive to nutrient availability, 
which is determined largely by the host diet.70 Changes in host 
enteral nutrition may change the nutrition selection pressures 
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within the gut, leading to an altered microbiome and influenc-
ing host pathological processes.71,72 Presumably, the lack of 
enteral feeding in the setting of complete intravenous nutrition 
results in sufficient nutrient delivery to the host while creating 
a nutrient-deprived environment for the bacteria within the gut. 
This hostile environment may select for Proteobacteria, which 
have been shown to survive in states of relative starvation, versus 
Firmicutes, which dominate in the nutrient-rich environment.73,74 
Aggressive microbiota such as Proteobacteria may then cause 
or exacerbate PN-associated inflammation by capitalizing on 
the reduced EBF that occurs with PN. Deplancke et al75 
explored this concept in the context of mucolysis, wherein 
bacteria metabolize mucin oligosaccharides. Using culture-
dependent methods, the investigators found that the ileal 
mucosa-associated microbiome from PN-dependent piglets 
was enriched for mucolytic bacteria, with opportunistic patho-
gen Clostridium perfringens significantly increased compared 
with enterally fed animals.75
Microbial Population Shifts, Immune 
Regulatory Changes
The mechanism by which the altered microbiome drives gut 
inflammatory dysregulation may be dependent on the myeloid 
differential primary response gene 88 (MyD88). A key func-
tion of the gut microbiota is to modulate the intestinal immune 
system by interacting with lamina propria (LP) cells, includ-
ing dendritic cells and macrophages.76,77 This interaction is 
mediated by Toll-like receptor binding. This pathway is 
dependent on MyD88 and leads to increased expression of 
proinflammatory cytokines TNF-α and IFN-γ, as previously 
discussed. There is also a loss of T-regulatory cells from the 
LP.58,78,79 When MyD88 knockout mice were used, a similar 
PN-associated population shift occurred in the mucosa-associ-
ated gut microbiome, characterized by a loss of Firmicutes 
and a predominance of Proteobacteria. PN-dependent MyD88 
knockout mice, however, exhibited preservation of EBF, 
increased epithelial cell proliferation, preserved regulatory 
cells population, and reduced proinflammatory cytokine sig-
naling compared with wild-type PN-dependent mice. This 
suggests that PN-associated shifts in the microbiome lead to 
downstream inflammatory effects and loss of EBF in a 
MyD88-dependent manner.58
Hepatic Complications
Given the wide-ranging pathological processes associated with 
the intestinal microbiome, it is not surprising that other 
PN-associated complications are also being attributed to spe-
cific gut microbial changes. Intestinal failure–associated liver 
disease (IFALD) is one of the principal end-stage complications 
of chronic PN dependence and remains the primary indication 
for intestinal transplantation.80 Characterized by cholestasis 
progressing to fibrosis and liver failure, the pathogenesis of 
IFALD is poorly understood.81 Several contributing factors 
have been implicated, including recurrent sepsis, excess sub-
strate or toxin delivery via PN, loss of gastrointestinal peptide 
production, increased bile viscosity, and bacterial translocation 
(Figure 2). Recent animal and human evidence suggests a role 
for the microbiome. In a mouse model of IFALD, the adminis-
tration of PN and induction of small bowel permeability led to 
expansion of the family Erysipelotrichaceae and subsequent 
TLR-4-mediated liver injury.82,83 Administration of antibiotics 
with reduction in this bacterial family attenuated the severity of 
liver injury.
Korpela et al84 recently evaluated the intestinal microbiota 
(from ileostomy, jejunostomy, or feces) as well as liver histo-
logic results of children with intestinal failure and compared 
these with healthy children. The abundance of Proteobacteria 
was associated with prolonged PN dependence and liver 
inflammation, whereas Lactobacilli were associated with chil-
dren who had been weaned off of PN and displayed liver ste-
atosis. Interestingly, the composition of the microbiota better 
predicted liver steatosis than did the duration of PN depen-
dence or the remaining intestinal length. This initial investiga-
tion reveals an intricate potential mechanism wherein an 
abundant Proteobacteria population, as in the PN-dependent 
state, results in liver inflammation, whereas Lactobacilli, 
which recover following weaning from PN, then mediate ste-
atosis. The use of antibiotic prophylaxis to lessen the bacterial 
burden for these patients has been suggested. Use of metroni-
dazole was retrospectively studied by Kubota et al85 in 21 
patients receiving prolonged PN. The authors reported a 
Figure 2. Intestinal failure–associated liver disease (IFALD). 
The pathogenesis of IFALD is likely multifactorial, with 
systemic factors, parenteral nutrition (PN)–associated factors, 
and gut-derived factors contributing to IFALD development. 
Increasing evidence suggests an altered microbiome predicts the 
development of IFALD. SMA, superior mesenteric artery.
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resultant decrease in transaminases; however, given the lack of 
other significant findings, antibiotics currently are used on a 
case-by-case basis depending on the clinical scenario at hand. 
The use of probiotics to support a healthy microbiome and 
decrease pathologic bacteria is the interest of other IFALD 
therapeutic studies.86 Despite evidence showing the prevention 
of bacterial translocation with probiotic administration in 
animal models87,88 and clinical improvement in small case 
studies,89,90 further human studies are necessary before routine 
use can be recommended. Given the association between 
enteric bacteria and liver injury in the setting of PN depen-
dence, further study to ascertain the exact nature of this rela-
tionship is warranted.
Conclusions and Future Studies
PN plays a critical role in fulfilling the nutrition needs of 
patients who cannot receive enteral nutrition. However, PN is 
associated with significant risks, culminating in potentially 
life-threatening complications such as sepsis and liver failure. 
The reduced EBF seen with PN dependence is driven by proin-
flammatory signaling derived from an altered microbial com-
munity, as summarized in Figure 3. The consequences of 
PN-associated changes in the microbiome include reduced 
EBF, systemic inflammatory responses, and liver injury. Better 
understanding of the factors contributing to these microbial 
shifts might reveal strategies to prevent PN-associated 
complications.
Future work should investigate the causal role of microbi-
ota in generating PN-induced disease. Like early investigations 
of other microbiome-driven diseases, studies to date largely 
provide associations between PN-associated microbial com-
munity changes and host pathophysiological features. Further 
studies should examine whether these microbial changes are 
sufficient to produce the PN-associated mucosal phenotype of 
epithelial barrier loss.
Questions remain regarding the role of the intestinal metab-
olome (ie, the metabolic composition of the intestinal lumen) 
in driving changes in the microbiome. In the PN-dependent 
state, no enteral nutrition is provided, significantly altering the 
availability of metabolic substrate for intestinal bacteria. The 
metabolic milieu present in the enterally deprived state has yet 
to be characterized, although this is likely a central factor in 
determining the makeup of the microbiota. It will be important 
to understand the available nutrients in the PN-dependent 
intestinal lumen, how these shape the bacterial community, and 
how bacteria in turn forage for nutrients both in the short term 
and with long-term PN administration.
Figure 3. Parenteral nutrition–associated changes in the microbiome and epithelial barrier dysfunction. (A) In the enterally fed state, 
intestinal epithelial barrier function is maintained by the interaction between Firmicutes-dominated intestinal microbiota and the host 
immune system. (B) With dependence on parenteral nutrition, the lack of enteral nutrients leads to an altered microbiome, characterized 
by increased Proteobacteria, which in turn drives a proinflammatory state in the intestinal mucosa, resulting in epithelial barrier 
dysfunction. EBF, epithelial barrier function; EGF, epidermal growth factor; IEL, intraepithelial lymphocyte; IFN, interferon; IL, 
interleukin; LPS, lipopolysaccharide; sIgA, secretory immunoglobulin A; TGF, transforming growth factor; TLR, Toll-like receptor; 
TNF, tumor necrosis factor; Treg, T-regulatory cell.
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The provision of adequate intraluminal nutrients for use by 
intestinal microbiota may attenuate microbiome-associated 
conditions. Using ever-improving methods of characterizing 
composition and function of the gut microbiota will likely 
reveal further insight into how bacteria are able to attain nutri-
ents in the state of enteral deprivation and what mechanisms 
these strains use to cause host disease. With continued study, 
improvements or adjuncts to PN therapy might allow for opti-
mization of the luminal environment, prevention of harmful 
shifts in the microbiota, and preservation of host barrier func-
tion and health.
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